Who are 14C-paliperidone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aripiprazole tablet, Risperidone and Ramelteon, Quetiapine (drug), Aripiprazole; Quetiapine, Lithium carbonate + perospirone hydrochloride, sodium valproate with Clozapine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/14c-paliperidone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

14C-paliperidone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

14C-paliperidone (14C-paliperidone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Neurology.

phase 1 Atypical antipsychotic Dopamine D2 receptor Neurology Small molecule Live · refreshed every 30 min

Target snapshot

14C-paliperidone (14C-paliperidone) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Dopamine D2 receptor antagonist

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
14C-paliperidone TARGET	14C-paliperidone	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 1	Atypical antipsychotic	Dopamine D2 receptor
Aripiprazole tablet	Aripiprazole tablet	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic	Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist)
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Quetiapine (drug)	Quetiapine (drug)	Medical University of Vienna	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Aripiprazole; Quetiapine	Aripiprazole; Quetiapine	Taichung Veterans General Hospital	marketed	Atypical antipsychotic combination	Dopamine D2 receptor; Serotonin 5-HT2A receptor; Serotonin 5-HT1A receptor
Lithium carbonate + perospirone hydrochloride	Lithium carbonate + perospirone hydrochloride	Shanghai Mental Health Center	marketed	Mood stabilizer + atypical antipsychotic combination	Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
sodium valproate with Clozapine	sodium valproate with Clozapine	Shanghai Mental Health Center	marketed	Antipsychotic + mood stabilizer combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

Shanghai Mental Health Center · 10 drugs in this class
AstraZeneca · 6 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
Eli Lilly and Company · 4 drugs in this class
Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
Medical University of Vienna · 2 drugs in this class
Organon and Co · 2 drugs in this class
Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
H. Lundbeck A/S · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 14C-paliperidone — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-paliperidone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing